McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Corporation

Millennium & Copthorne Hotels New Zealand Limited ( ($NZ:MCK) ) has shared an announcement. Millennium & Copthorne Hotels New Zealand reported a st...

Millennium & Copthorne lifts hotel revenue, starts 2026 strongly amid global uncertainty

Millennium & Copthorne Hotels New Zealand Limited ( ($NZ:MCK) ) just unveiled an announcement. Millennium & Copthorne Hotels New Zealand shareholde...

Millennium & Copthorne NZ Shareholders Back Board at 2026 AGM

In a report released on May 20, Pallav Mittal from Barclays maintained a Hold rating on Svenska Cellulosa SCA AB, with a price target of SEK92.00. ...

Svenska Cellulosa SCA AB (0MCK) Receives a Hold from Barclays

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on McKesson, with a price target of $812.00. The company’s...

Wells Fargo Reaffirms Their Hold Rating on McKesson (MCK)

Bank of America Securities analyst Allen Lutz reiterated a Buy rating on McKesson today and set a price target of $900.00. According to TipRanks, L...

McKesson (MCK) Gets a Buy from Bank of America Securities

Barclays analyst Glen Santangelo maintained a Buy rating on McKesson today and set a price target of $1,050.00. Santangelo covers the Healthcare se...

McKesson (MCK) Gets a Buy from Barclays

An update from Svenska Cellulosa SCA AB ( ($SE:SCA.B) ) is now available. Svenska Cellulosa SCA has appointed Klas Nilsson as its new Senior Vice P...

SCA Names Klas Nilsson as New SVP for Sustainability and Communications

Analysts are intrested in these 5 stocks: ( ($CAH) ), ( ($MCK) ), ( ($ZETA) ), ( ($CNC) ) and ( ($ABAT) ). Here is a breakdown of their recent


Cardinal, McKesson, Zeta, Centene, ABAT Trending With Analysts

Millennium & Copthorne Hotels New Zealand Limited ( ($NZ:MCK) ) has shared an update. Millennium & Copthorne Hotels New Zealand has issued its 2026...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MCK	$754.40	-1.52%	1.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MCK	$754.40	-1.5%	1.98M
3
4
5
6

MCK

MCK

Get McKesson Corporation Data in Excel

Get McKesson Corporation Data in Excel